Tom Burt

Partner, Crossover Fund


Tom joined Sofinnova in June 2017 from Peel Hunt where he is senior research analyst in Healthcare & Life Sciences. Tom has 11 years of experience in life sciences venture and private company investing, equity and alternative financing (hybrid and debt instruments).

He has worked for several years with Jacques Theurillat at Ares Life Sciences. Prior to that, he was at Novo Growth Equity; a Danish fund focused on late-stage investments in both public/private life science companies and a member of Piper Jaffray’s European Healthcare investment banking team. He thus has diverse investing expertise throughout the company’s life cycle (early-stage to commercial) with over $1.5bn in total completed transactions.

During this time he has been actively involved in strategy and operations of multinational portfolio companies in the healthcare domain and has deep financial and transactional experience in both public and private, late-stage life sciences companies in the US and in Europe.

He holds a Doctorate and Masters degrees in Biochemical Engineering (University College London and University of Birmingham) and undergraduate degree in Biotechnology.